Clinical Trials Directory

Trials / Completed

CompletedNCT05706233

Erector Spinae Plane Block as a Rescue Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy

Effect of Postoperative Erector Spinae Plane Block as a Rescue Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy: A Historical Cohort Study

Status
Completed
Phase
Study type
Observational
Enrollment
108 (actual)
Sponsor
Istanbul Saglik Bilimleri University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers

Summary

Laparoscopic cholecystectomy, one of the most commonly performed abdominal surgeries, is a gold standard therapy for surgical treatment of benign biliary diseases. Erector spinae plane block (ESPB) was first presented in 2016 as the treatment of neuropathic pain in a case series, and gained popularity very quickly due to its safety applicability, and effect on both the visceral and parietal component of pain by providing paravertebral, transforaminal and epidural spread. Preoperative application of ESPB has taken its place as a part of multimodal analgesia in laparoscopic cholecystectomy cases over time and has been shown to reduce postoperative pain scores and opioid consumption and to improve quality of recovery scores. However, there is no data regarding the use of ESPB in the postoperative period as a rescue therapy.

Conditions

Interventions

TypeNameDescription
PROCEDUREErector Spina Plane GroupESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
PROCEDUREIV analgesic interventionIV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.

Timeline

Start date
2022-02-15
Primary completion
2022-05-15
Completion
2022-05-15
First posted
2023-01-31
Last updated
2023-06-28

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05706233. Inclusion in this directory is not an endorsement.